Supernus Pharmaceuticals EBITDA 2012-2026 | SUPN
Supernus Pharmaceuticals ebitda from 2012 to 2026. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
|
Supernus Pharmaceuticals Annual EBITDA (Millions of US $) |
|
|---|---|
| 2025 | $28 |
| 2024 | $164 |
| 2023 | $80 |
| 2022 | $137 |
| 2021 | $137 |
| 2020 | $206 |
| 2019 | $167 |
| 2018 | $162 |
| 2017 | $107 |
| 2016 | $57 |
| 2015 | $23 |
| 2014 | $-2 |
| 2013 | $-58 |
| 2012 | $-41 |
| 2011 | $-37 |
|
Supernus Pharmaceuticals Quarterly EBITDA (Millions of US $) |
|
|---|---|
| 2026-06-30 | $-33 |
| 2026-03-31 | $18 |
| 2025-12-31 | $22 |
| 2025-09-30 | $-36 |
| 2025-06-30 | $33 |
| 2025-03-31 | $9 |
| 2024-12-31 | $40 |
| 2024-09-30 | $62 |
| 2024-06-30 | $43 |
| 2024-03-31 | $19 |
| 2023-12-31 | $21 |
| 2023-09-30 | $30 |
| 2023-06-30 | $3 |
| 2023-03-31 | $25 |
| 2022-12-31 | $56 |
| 2022-09-30 | $23 |
| 2022-06-30 | $35 |
| 2022-03-31 | $23 |
| 2021-12-31 | $25 |
| 2021-09-30 | $45 |
| 2021-06-30 | $44 |
| 2021-03-31 | $22 |
| 2020-12-31 | $53 |
| 2020-09-30 | $64 |
| 2020-06-30 | $54 |
| 2020-03-31 | $35 |
| 2019-12-31 | $45 |
| 2019-09-30 | $44 |
| 2019-06-30 | $48 |
| 2019-03-31 | $30 |
| 2018-12-31 | $46 |
| 2018-09-30 | $43 |
| 2018-06-30 | $39 |
| 2018-03-31 | $34 |
| 2017-12-31 | $36 |
| 2017-09-30 | $27 |
| 2017-06-30 | $27 |
| 2017-03-31 | $17 |
| 2016-12-31 | $17 |
| 2016-09-30 | $21 |
| 2016-06-30 | $12 |
| 2016-03-31 | $7 |
| 2015-12-31 | $8 |
| 2015-09-30 | $6 |
| 2015-06-30 | $4 |
| 2015-03-31 | $4 |
| 2014-12-31 | $6 |
| 2014-09-30 | $0 |
| 2014-06-30 | $5 |
| 2014-03-31 | $-13 |
| 2013-12-31 | $-10 |
| 2013-09-30 | $-16 |
| 2013-06-30 | $-15 |
| 2013-03-31 | $-18 |
| 2012-12-31 | $-12 |
| 2012-09-30 | $-12 |
| 2012-06-30 | $-9 |
| 2012-03-31 | $-8 |
| 2011-12-31 | $-10 |
| 2011-09-30 | $-10 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $2.409B | $0.719B |
| Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| BridgeBio Pharma (BBIO) | United States | $13.352B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |